Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Oxymetazoline

A nasal decongestant of the imidazoline family that narrows blood vessels by stimulating alpha-adrenergic receptors; it was developed in Germany in 1961 by Wolfgang Fruhstorfer and Helmut Müller-Calgan. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?The same ingredient that clears a blocked nose has been approved in the United States as a cream for rosacea redness (2017) and as eye drops to lift a drooping eyelid (2020).

OxymetazolineGo to the active ingredient →
OxymetazolineActive ingredientOxymetazolineCat. No. P-O073-001CAS 1491-59-4

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.